Invitae Reports Third Quarter 2023 Financial Results

Rhea-AI Summary

NVTA: Invitae Reports $121.2M Q3 Revenue, 9% YoY Decrease; Pro Forma Revenue Up 4%; Gross Margin 32.2%; Reaffirms 2023 Guidance

Positive

• Revenue decreased 9% year-over-year to $121.2 million, but pro forma revenue increased approximately 4%, indicating potential growth.
• Gross margin improved to 32.2% from 12.4% in the previous year, showing a positive trend in profitability.
• The company reaffirms its 2023 financial guidance, demonstrating confidence in future performance.
• The number of patients served as of September 30, 2023, was approximately 4.4 million, indicating a significant market presence.

Negative

• Operating expenses for the third quarter of 2023 were $1.0 billion, significantly higher than the $306.5 million in the third quarter of 2022, raising concerns about cost management.
• Net decrease in cash, cash equivalents, restricted cash, and net changes in investments in the quarter was $72.2 million, indicating a substantial reduction in liquidity.

Reported revenue of $121.2 million, a year-over-year decrease of 9%; on a pro forma basis, taking into account exited businesses and geographies, revenue increased approximately 4%

Gross margin of 32.2% and non-GAAP gross margin of 52.4%; continued improvement in non-GAAP gross margin for nine consecutive quarters

Reaffirming 2023 financial guidance

SAN FRANCISCO, Nov. 8, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced results for the third quarter ended September 30, 2023.

"The Company executed well on key operating and financial metrics in the third quarter, and remains on track to meet or beat annual guidance," said Ken Knight, president and chief executive officer of Invitae. "On the operational front, we added key executive talent and achieved a number of clinical milestones that should strengthen the health of our business, deliver continuing market expansion and further differentiate our testing portfolio from competitors."

Third Quarter 2023 Financial Results

• Third quarter revenue decreased 9% to $121.2 million compared to $133.5 million in the same period in the prior year, primarily reflecting the impact of exited businesses and geographies completed in 2022. After adjusting for revenue of $17.2 million in the prior year period related to the discontinued businesses, third quarter revenue increased approximately 4% on a pro forma basis, with U.S. hereditary cancer testing volume achieving double-digit percentage growth compared to the prior year period.
• Gross profit was $39.1 million in the quarter, compared with $16.6 million in the same period of 2022, or 135.6% year-over-year growth. Non-GAAP gross profit was $63.6 million in the quarter, compared with $61.2 million in the third quarter of 2022, representing a year-over-year growth rate of 3.8%.
• Gross margin was 32.2% in the third quarter, compared with 12.4% a year ago. Non-GAAP gross margin was 52.4% compared with 45.9% in the third quarter of 2022. This represents Invitae's ninth consecutive quarter of non-GAAP gross margin improvement.
• Operating expense for the third quarter of 2023 was $1.0 billion, compared with $306.5 million in the third quarter of 2022. Operating expense in the third quarter includes $877.3 million in restructuring, impairment and other costs primarily related to an impairment charge of the Company's long-lived assets, compared with $125.2 million in the prior year period. Non-GAAP operating expense was $122.1 million for the third quarter of 2023, compared with $150.0 million for the third quarter of 2022. Non-GAAP operating expense as a percentage of revenue was 101%, compared with 112% in the third quarter of 2022.
• As of September 30, 2023, Invitae had $264.7 million of cash, cash equivalents, restricted cash and marketable securities compared to $557.1 million as of December 31, 2022.
• Net decrease in cash, cash equivalents, restricted cash and net changes in investments in the quarter was $72.2 million. Cash burn in the quarter was $64.1 million.
• Total patients served as of September 30, 2023 was approximately 4.4 million with 64% available for data sharing.
• Third quarter net loss per basic and diluted share of ($3.42) included impairment and losses on disposals of long-lived assets, net, employee severance and benefits and other restructuring costs of $877.3 million primarily related to fair market value assessment of the Company's intangible assets. Third quarter non-GAAP net loss per basic and diluted share of ($0.10) excludes this charge. Compared to a year ago, net loss per basic and diluted share and non-GAAP net loss per basic and diluted share were ($1.27) and ($0.42), respectively.

Operational improvement efforts and expense control have resulted in margin expansion and stronger financial performance. In addition, the Company is engaging with stakeholders to strengthen the balance sheet, and the Board of Directors has formed a special committee focused on improving the Company's capital structure. The Company is exploring a number of options, including, but not limited to, raising capital, asset sales, business and R&D refocusing efforts, capital expenditure and operating expense reductions and addressing its debt obligations.

Reaffirming Fiscal 2023 Outlook

For the full year, Invitae is reaffirming its fiscal 2023 outlook. The Company expects revenue in the range of $480-$500 million and non-GAAP gross margin in the range of 48-50%.

Ongoing cash burn includes cash, cash equivalents, marketable securities and restricted cash and excludes certain items. The Company continues to expect ongoing cash burn to be in the range of $220-$245 million in 2023. In 2023, cash burn will be higher than ongoing cash burn as a result of the Company's voluntary repayment of its $135 million term loan in the first quarter of 2023. 

Webcast and Conference Call Details

Management will host a conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss financial results and recent developments. To access the conference call, please register at the link below:

https://www.netroadshow.com/events/login?show=62d0dec5&confId=56925 

Upon registering, each participant will be provided with call details and access codes. 

The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website.

About Invitae
Invitae (NYSE: NVTA) is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We aim to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of their mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.

To learn more, visit invitae.com and follow for updates on Twitter, Instagram, Facebook and LinkedIn @Invitae.

Safe Harbor Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's mission; the company's future financial and operating results; the company's focus, strategy, and roadmap; the company's financial guidance for 2023; the company's belief that the addition of executives and achievement of clinical milestones will strengthen the health of the company's business, deliver continuing market expansion and differentiate the company's testing portfolio from competitors; the objectives of the special committee; and the company's beliefs regarding engagement with stakeholders and plans to explore various options. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the availability of and need for capital; the ability to service the company's debt obligations; the ability of the company to successfully execute its strategic business realignment and achieve the intended benefits thereof on the expected timeframe or at all; unforeseen or greater than expected costs associated with the strategic business realignment; the risk that the disruption that may result from the realignment may harm the company's business, market share or its relationship with customers or potential customers; risks related to the various options the company is exploring, including the fact that certain options may not be available to the company; the impact of inflation and the current economic environment on the company's business; the company's ability to grow its business in a cost-efficient manner; the company's history of losses; the company's ability to maintain important customer relationships; the company's ability to compete; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the applicability of clinical results to actual outcomes; risks associated with litigation; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; laws and regulations applicable to the company's business; and the other risks set forth in the reports filed by the company with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.

Non-GAAP Financial Measures
To supplement the company's consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP), the company is providing several non-GAAP measures. These non-GAAP financial measures exclude certain items that are required by GAAP. In addition, these non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly-titled measures presented by other companies. Management believes these non-GAAP financial measures are useful to investors in evaluating the company's ongoing operating results and trends. Management uses such non-GAAP information to manage the company's business and monitor its performance.

Other companies, including companies in the same industry, may not use the same non-GAAP measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. Because of these limitations, the company's non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Investors are encouraged to review the non-GAAP reconciliations provided in the tables below and on the company's website.

In addition, this press release includes the company's non-GAAP gross margin and cash burn guidance, non-GAAP measures used to describe the company's expected performance. The company has not presented a reconciliation of these non-GAAP measures to the most comparable GAAP financial measures, because the reconciliations could not be prepared without unreasonable effort. The information necessary to prepare the reconciliations are not available on a forward-looking basis and cannot be accurately predicted. The unavailable information could have a significant impact on the calculation of the comparable GAAP financial measures.

Invitae Contacts:

Investor Relations
Hoki Luk  
ir@invitae.com

Public Relations
Amy Hadsock  
pr@invitae.com 

 

INVITAE CORPORATION Condensed Consolidated Balance Sheets (in thousands) (unaudited)
	September 30, 2023		December 31, 2022
Assets
Current assets:
Cash and cash equivalents	$        158,007		$        257,489
Marketable securities	96,566		289,611
Accounts receivable	82,507		96,148
Inventory	21,627		30,386
Prepaid expenses and other current assets	19,692		19,496
Total current assets	378,399		693,130
Property and equipment, net	65,446		108,723
Operating lease assets	61,639		106,563
Restricted cash	10,100		10,030
Intangible assets, net	—		1,012,549
Other assets	19,531		23,121
Total assets	$        535,115		$     1,954,116
Liabilities and stockholders' (deficit) equity
Current liabilities:
Accounts payable	$    25,185		$    13,984
Accrued liabilities	84,729		74,388
Operating lease obligations	17,650		14,600
Finance lease obligations	3,948		5,121
Convertible senior notes, net current portion	26,907		—
Total current liabilities	158,419		108,093
Operating lease obligations, net of current portion	134,945		134,386
Finance lease obligations, net of current portion	855		3,780
Debt	—		122,333
Convertible senior notes, net	1,127,830		1,470,783
Convertible senior secured notes (at fair value)	196,244		—
Deferred tax liability	—		8,130
Other long-term liabilities	226		4,775
Total liabilities	1,618,519		1,852,280
Stockholders' (deficit) equity:
Common stock	29		25
Accumulated other comprehensive income (loss)	25,378		(80)
Additional paid-in capital	5,061,131		4,931,032
Accumulated deficit	(6,169,942)		(4,829,141)
Total stockholders' (deficit) equity	(1,083,404)		101,836
Total liabilities and stockholders' (deficit) equity	$        535,115		$     1,954,116

 

INVITAE CORPORATION Condensed Consolidated Statements of Operations (in thousands, except per share data) (unaudited)
		Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022
Revenue:
Test revenue		$         117,561		$         128,839		$         346,127		$         381,518
Other revenue		3,680		4,697		13,002		12,331
Total revenue		121,241		133,536		359,129		393,849
Operating expenses:
Cost of revenue		82,186		116,956		258,102		324,412
Research and development		58,336		87,177		184,138		330,559
Selling and marketing		37,999		49,193		127,241		172,086
General and administrative		45,619		44,939		160,826		147,221
Goodwill and IPR&D impairment		—		—		—		2,313,047
Restructuring, impairment and other costs		877,289		125,222		1,010,843		130,039
Total operating expenses		1,101,429		423,487		1,741,150		3,417,364
Loss from operations		(980,188)		(289,951)		(1,382,021)		(3,023,515)
Other income (expense), net:
Gain (loss) on extinguishment of debt, net		229		—		(10,593)		—
Debt issuance costs		(845)		—		(20,704)		—
Change in fair value of convertible senior secured notes		33,463		—		72,386		—
Change in fair value of acquisition-related liabilities		70		(527)		337		15,666
Other income, net		4,843		2,399		15,105		3,971
Total other income, net		37,760		1,872		56,531		19,637
Interest expense		(5,850)		(14,145)		(23,366)		(42,149)
Net loss before taxes		(948,278)		(302,224)		(1,348,856)		(3,046,027)
Income tax benefit		6,171		1,068		8,055		39,551
Net loss		$     (942,107)		$     (301,156)		$  (1,340,801)		$    (3,006,476)
Net loss per share, basic and diluted		$          (3.42)		$          (1.27)		$          (5.09)		$          (12.91)
Shares used in computing net loss per share, basic and diluted		275,604		237,974		263,210		232,889

 

INVITAE CORPORATION Condensed Consolidated Statements of Cash Flows (in thousands) (unaudited)
	Nine Months Ended September 30,
	2023		2022
Cash flows from operating activities:
Net loss	$         (1,340,801)		$         (3,006,476)
Adjustments to reconcile net loss to net cash used in operating activities:
Goodwill and IPR&D impairment	—		2,313,047
Impairments and losses on disposals of long-lived assets, net	1,012,360		60,317
Depreciation and amortization	100,403		104,726
Stock-based compensation	85,554		164,314
Amortization of debt discount and issuance costs	5,483		11,676
Loss on extinguishment of debt, net	10,593		—
Debt issuance costs	20,704		—
Change in fair value of convertible senior secured notes	(72,386)		—
Remeasurements of liabilities associated with business combinations	(337)		(15,666)
Benefit from income taxes	(8,055)		(39,551)
Post-combination expense for acceleration of unvested equity and deferred stock compensation	1,789		4,980
Amortization of premiums and discounts on investment securities	(6,259)		603
Non-cash lease expense	9,309		6,832
Other	2,211		(1,314)
Changes in operating assets and liabilities, net of businesses acquired:
Accounts receivable	13,641		(22,903)
Inventory	8,759		3,614
Prepaid expenses and other current assets	(196)		9,012
Other assets	(139)		2,740
Accounts payable	8,135		(6,345)
Accrued expenses and other long-term liabilities	(6,966)		(540)
Net cash used in operating activities	(156,198)		(410,934)
Cash flows from investing activities:
Purchases of marketable securities	(231,044)		(789,622)
Proceeds from maturities of marketable securities	430,440		541,313
Purchases of property and equipment	(4,669)		(48,385)
Proceeds from sale of property and equipment	332		—
Net cash provided by (used in) investing activities	195,059		(296,694)
Cash flows from financing activities:
(Loss) proceeds from public offerings of common stock, net of issuance costs	(55)		9,658
Proceeds from issuance of common stock, net	2,170		6,267
Proceeds from issuance of Series B convertible senior secured notes due 2028	30,001		—
Payments for debt issuance costs and prepayment fees	(25,974)		—
Repayment of debt	(135,000)		—
Finance lease principal payments	(3,886)		(4,184)
Settlement of acquisition obligations	(5,529)		(10,582)
Net cash (used in) provided by financing activities	(138,273)		1,159
Net decrease in cash, cash equivalents and restricted cash	(99,412)		(706,469)
Cash, cash equivalents and restricted cash at beginning of period	267,519		933,525
Cash, cash equivalents and restricted cash at end of period	$                168,107		$                227,056

 

Reconciliation of GAAP to Non-GAAP Cost of Revenue (in thousands) (unaudited)
		Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022
Cost of revenue		$        82,186		$       116,956		$      258,102		$      324,412
Amortization of acquired intangible assets		(24,082)		(27,711)		(77,122)		(73,618)
Acquisition-related stock-based compensation		(44)		(146)		(146)		(425)
Acquisition-related post-combination expense		—		(162)		—		(1,053)
Restructuring-related retention bonuses		(7)		(170)		(145)		(170)
Inventory and prepaid write-offs		(388)		(16,467)		(1,362)		(16,467)
Non-GAAP cost of revenue		$        57,665		$        72,300		$      179,327		$      232,679

 

Reconciliation of GAAP to Non-GAAP Gross Profit (in thousands) (unaudited)
		Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022
Revenue		$      121,241		$      133,536		$      359,129		$      393,849
Cost of revenue		82,186		116,956		258,102		324,412
Gross profit		39,055		16,580		101,027		69,437
Amortization of acquired intangible assets		24,082		27,711		77,122		73,618
Acquisition-related stock-based compensation		44		146		146		425
Acquisition-related post-combination expense		—		162		—		1,053
Restructuring-related retention bonuses		7		170		145		170
Inventory and prepaid write-offs		388		16,467		1,362		16,467
Non-GAAP gross profit		$        63,576		$        61,236		$      179,802		$      161,170

 

Reconciliation of GAAP to Non-GAAP Research and Development Expense (in thousands) (unaudited)
		Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022
Research and development		$        58,336		$        87,177		$      184,138		$      330,559
Amortization of acquired intangible assets		—		(306)		(90)		(1,338)
Acquisition-related stock-based compensation		(14,921)		(18,695)		(43,448)		(65,719)
Acquisition-related post-combination expense		(141)		(1,962)		(1,825)		(7,186)
Restructuring-related retention bonuses		(669)		(646)		(2,052)		(646)
Restructuring-related accelerated depreciation		(125)		(3,311)		(341)		(3,311)
Non-GAAP research and development		$        42,480		$        62,257		$      136,382		$      252,359

 

Reconciliation of GAAP to Non-GAAP Selling and Marketing Expense (in thousands) (unaudited)
		Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022
Selling and marketing		$        37,999		$        49,193		$      127,241		$      172,086
Amortization of acquired intangible assets		(1,569)		(1,610)		(4,707)		(4,856)
Acquisition-related stock-based compensation		—		(806)		(750)		(2,374)
Restructuring-related retention bonuses		(105)		(115)		(565)		(115)
Non-GAAP selling and marketing		$        36,325		$        46,662		$      121,219		$      164,741

 

Reconciliation of GAAP to Non-GAAP General and Administrative Expense (in thousands) (unaudited)
		Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022
General and administrative		$        45,619		$        44,939		$      160,826		$      147,221
Change in fair value of contingent consideration		—		—		—		1,850
Acquisition-related stock-based compensation		(1,181)		(3,438)		(3,524)		(6,656)
Restructuring-related retention bonuses		(1,149)		(300)		(2,402)		(300)
Restructuring-related accelerated depreciation		—		(111)		—		(111)
Non-GAAP general and administrative		$        43,289		$        41,090		$      154,900		$      142,004

 

Reconciliation of Operating Expenses to Non-GAAP Operating Expenses (in thousands) (unaudited)
		Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022
Research and development		$        58,336		$        87,177		$       184,138		$       330,559
Selling and marketing		37,999		49,193		127,241		172,086
General and administrative		45,619		44,939		160,826		147,221
Goodwill and IPR&D impairment		—		—		—		2,313,047
Restructuring, impairment and other costs		877,289		125,222		1,010,843		130,039
Operating expenses		1,019,243		306,531		1,483,048		3,092,952
Goodwill and IPR&D impairment		—		—		—		(2,313,047)
Restructuring, impairment and other costs		(877,289)		(125,222)		(1,010,843)		(130,039)
Change in fair value of contingent consideration		—		—		—		1,850
Amortization of acquired intangible assets		(1,569)		(1,916)		(4,797)		(6,194)
Acquisition-related stock-based compensation		(16,102)		(22,939)		(47,722)		(74,749)
Acquisition-related post-combination expense		(141)		(1,962)		(1,825)		(7,186)
Restructuring-related retention bonuses		(1,923)		(1,061)		(5,019)		(1,061)
Restructuring-related accelerated depreciation		(125)		(3,422)		(341)		(3,422)
Non-GAAP operating expenses		$      122,094		$      150,009		$       412,501		$       559,104

 

Reconciliation of Other Income, Net to Non-GAAP Other Income, Net (in thousands) (unaudited)
		Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022
Other income, net		$        37,760		$          1,872		$        56,531		$        19,637
Change in fair value of acquisition-related liabilities		(70)		527		(337)		(15,666)
Non-GAAP other income, net		$        37,690		$          2,399		$        56,194		$          3,971

 

Reconciliation of Net Loss to Non-GAAP Net Loss and Non-GAAP Net Loss Per Share (in thousands, except per share data) (unaudited)
		Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022
Net loss		$     (942,107)		$     (301,156)		$  (1,340,801)		$  (3,006,476)
Goodwill and IPR&D impairment		—		—		—		2,313,047
Restructuring, impairment and other costs		877,289		125,222		1,010,843		130,039
Change in fair value of contingent consideration		—		—		—		(1,850)
Change in fair value of acquisition-related assets and liabilities		(70)		527		(337)		(15,666)
Amortization of acquired intangible assets		25,651		29,627		81,919		79,812
Acquisition-related stock-based compensation		16,146		23,085		47,868		75,174
Acquisition-related post-combination expense		141		2,124		1,825		8,239
Restructuring-related retention bonuses		1,930		1,231		5,164		1,231
Restructuring-related accelerated depreciation		125		3,422		341		3,422
Inventory and prepaid write-offs		388		16,467		1,362		16,467
Acquisition-related income tax benefit		(6,180)		(1,390)		(6,810)		(40,195)
Non-GAAP net loss		$       (26,687)		$     (100,841)		$     (198,626)		$     (436,756)
Net loss per share, basic and diluted		$          (3.42)		$          (1.27)		$          (5.09)		$         (12.91)
Non-GAAP net loss per share, basic and diluted		$          (0.10)		$          (0.42)		$          (0.75)		$          (1.88)
Shares used in computing net loss per share, basic and diluted		275,604		237,974		263,210		232,889

 

Reconciliation of Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash to Cash Burn (in thousands) (unaudited)
	Three Months Ended						Nine Months Ended
	March 31, 2023		June 30, 2023		September 30, 2023		September 30, 2023
Net cash used in operating activities	$      (34,398)		$      (54,905)		$         (66,895)		$       (156,198)
Net cash provided by investing activities	73,878		116,064		5,117		195,059
Net cash (used in) provided by financing activities	(135,768)		876		(3,381)		(138,273)
Net (decrease) increase in cash, cash equivalents and restricted cash	(96,288)		62,035		(65,159)		(99,412)
Adjustments:
Net changes in investments	(75,202)		(117,146)		(7,048)		(199,396)
Loss from public offerings of common stock, net of issuance costs	—		—		55		55
Proceeds from issuance of Series B convertible senior secured notes due 2028, net of issuance costs	(22,435)		1,763		8,016		(12,656)
Cash burn	$    (193,925)		$      (53,348)		$         (64,136)		$       (311,409)
• Cash burn for the three months ended March 31, 2023 includes $135.0 million repayment of debt, $8.1 million of prepayment fees, $3.7 million in restructuring-related cash payments, and $1.5 million of acquisition-related payments.
• Cash burn for the three months ended September 30, 2023 includes $4.1 million of acquisition-related payments.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/invitae-reports-third-quarter-2023-financial-results-301982255.html

SOURCE Invitae Corporation

FAQ

What was Invitae's third quarter revenue?

Invitae reported a revenue of $121.2 million for the third quarter, representing a 9% decrease year-over-year.

What was the gross margin in the third quarter?

The gross margin for Invitae in the third quarter was 32.2%, showing a significant improvement from the previous year.

What is Invitae's 2023 financial guidance?

Invitae reaffirms its 2023 financial guidance, expecting revenue in the range of $480-$500 million and non-GAAP gross margin in the range of 48-50%.

How many patients does Invitae serve?

Invitae served approximately 4.4 million patients as of September 30, 2023, with 64% available for data sharing.